JP2013516978A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013516978A5 JP2013516978A5 JP2012548518A JP2012548518A JP2013516978A5 JP 2013516978 A5 JP2013516978 A5 JP 2013516978A5 JP 2012548518 A JP2012548518 A JP 2012548518A JP 2012548518 A JP2012548518 A JP 2012548518A JP 2013516978 A5 JP2013516978 A5 JP 2013516978A5
- Authority
- JP
- Japan
- Prior art keywords
- adenovirus
- seq
- preproendothelin promoter
- mouse preproendothelin
- transgene
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 claims description 96
- 241000701161 unidentified adenovirus Species 0.000 claims description 47
- 101800004490 Endothelin-1 Proteins 0.000 claims description 42
- 108091033319 polynucleotide Proteins 0.000 claims description 31
- 102000040430 polynucleotide Human genes 0.000 claims description 31
- 239000002157 polynucleotide Substances 0.000 claims description 31
- 230000003362 replicative effect Effects 0.000 claims description 25
- 239000002773 nucleotide Substances 0.000 claims description 23
- 125000003729 nucleotide group Chemical group 0.000 claims description 23
- 108700019146 Transgenes Proteins 0.000 claims description 18
- 241000700605 Viruses Species 0.000 claims description 16
- 238000012258 culturing Methods 0.000 claims description 13
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 11
- 150000007523 nucleic acids Chemical group 0.000 claims description 11
- 239000008194 pharmaceutical composition Substances 0.000 claims description 8
- 238000002360 preparation method Methods 0.000 claims description 7
- 206010028980 Neoplasm Diseases 0.000 claims description 6
- 230000001023 pro-angiogenic effect Effects 0.000 claims description 6
- 108700025910 Suicide Transgenic Genes Proteins 0.000 claims description 5
- 230000001772 anti-angiogenic effect Effects 0.000 claims description 4
- 230000003612 virological effect Effects 0.000 claims description 4
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 3
- 239000004480 active ingredient Substances 0.000 claims description 3
- 238000004115 adherent culture Methods 0.000 claims description 3
- 230000033115 angiogenesis Effects 0.000 claims description 3
- 239000004037 angiogenesis inhibitor Substances 0.000 claims description 3
- 230000001640 apoptogenic effect Effects 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims description 3
- 238000011031 large-scale manufacturing process Methods 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 108090000623 proteins and genes Proteins 0.000 claims description 3
- 238000001542 size-exclusion chromatography Methods 0.000 claims description 3
- 238000004114 suspension culture Methods 0.000 claims description 3
- 229940124597 therapeutic agent Drugs 0.000 claims description 3
- 238000001990 intravenous administration Methods 0.000 claims description 2
- 238000004255 ion exchange chromatography Methods 0.000 claims description 2
- 230000000692 anti-sense effect Effects 0.000 claims 3
- 201000011510 cancer Diseases 0.000 claims 2
- 238000007911 parenteral administration Methods 0.000 claims 2
- 206010061289 metastatic neoplasm Diseases 0.000 claims 1
- AIYUHDOJVYHVIT-UHFFFAOYSA-M caesium chloride Chemical compound [Cl-].[Cs+] AIYUHDOJVYHVIT-UHFFFAOYSA-M 0.000 description 4
- 241001135569 Human adenovirus 5 Species 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 102000006601 Thymidine Kinase Human genes 0.000 description 2
- 108020004440 Thymidine kinase Proteins 0.000 description 2
- 108091092356 cellular DNA Proteins 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 238000009295 crossflow filtration Methods 0.000 description 2
- 238000003306 harvesting Methods 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 229920005654 Sephadex Polymers 0.000 description 1
- 239000012507 Sephadex™ Substances 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 238000005571 anion exchange chromatography Methods 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 238000011033 desalting Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 238000005199 ultracentrifugation Methods 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US29415810P | 2010-01-12 | 2010-01-12 | |
| US61/294,158 | 2010-01-12 | ||
| PCT/IB2011/050137 WO2011086509A1 (en) | 2010-01-12 | 2011-01-12 | Methods of producing adenovirus vectors and viral preparations generated thereby |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013516978A JP2013516978A (ja) | 2013-05-16 |
| JP2013516978A5 true JP2013516978A5 (enExample) | 2014-02-27 |
| JP6009357B2 JP6009357B2 (ja) | 2016-10-19 |
Family
ID=43982270
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012548518A Expired - Fee Related JP6009357B2 (ja) | 2010-01-12 | 2011-01-12 | アデノウイルスベクターの生産方法およびそれによって生成されるウイルス調製物 |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US20130052165A1 (enExample) |
| EP (1) | EP2523681A1 (enExample) |
| JP (1) | JP6009357B2 (enExample) |
| IL (1) | IL220922B (enExample) |
| SG (2) | SG10201500015TA (enExample) |
| WO (1) | WO2011086509A1 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8071740B2 (en) * | 2000-11-17 | 2011-12-06 | Vascular Biogenics Ltd. | Promoters exhibiting endothelial cell specificity and methods of using same for regulation of angiogenesis |
| AU2003222427B8 (en) * | 2000-11-17 | 2010-04-29 | Vascular Biogenics Ltd. | Promoters exhibiting endothelial cell specificity and methods of using same |
| CA2463816C (en) | 2001-10-19 | 2014-07-08 | Vascular Biogenics Ltd. | Polynucleotide constructs, pharmaceutical compositions and methods for targeted downregulation of angiogenesis and anticancer therapy |
| CA2658972C (en) | 2006-07-31 | 2019-11-26 | Vascular Biogenics Ltd. | Polypeptides and polynucleotides encoding same and use thereof in the treatment of medical conditions associated with ischemia |
| DK2521776T3 (en) | 2010-01-05 | 2017-02-13 | Vascular Biogenics Ltd | METHODS FOR USING A SPECIFIC ANTI-ANGIOGENT ADENOVIRAL AGENT |
| CA2786377C (en) | 2010-01-05 | 2018-02-27 | Vascular Biogenics Ltd. | Compositions and methods for treating malignant gliomas employing viral vectors encoding a fas-chimera |
| DK2908865T3 (en) * | 2012-10-17 | 2019-01-28 | Vascular Biogenics Ltd | ADENOVIRUS THAT EXPRESSES A PHAS-CHIMARY AND ITS APPLICATION IN CANCER TREATMENT METHODS |
| CN103012591B (zh) * | 2012-12-12 | 2014-05-14 | 武汉吉爱生物技术有限公司 | 抗Benzonase单克隆抗体、其制备方法和应用 |
| EP2951307B1 (en) | 2013-02-04 | 2019-12-25 | Vascular Biogenics Ltd. | Methods of inducing responsiveness to anti-angiogenic agent |
| CN105378074A (zh) * | 2013-03-15 | 2016-03-02 | 费城儿童医院 | 在无血清悬浮细胞培养系统中生产重组慢病毒载体的可扩大的制造方法 |
| CN107603956A (zh) * | 2017-08-24 | 2018-01-19 | 乾元浩生物股份有限公司 | 一种禽腺病毒纸片载体潮汐式悬浮培养方法 |
| CN107630004B (zh) * | 2017-09-01 | 2021-01-15 | 康希诺生物股份公司 | 降低可复制性腺病毒产生的细胞株及构建方法和应用 |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL154600B (nl) | 1971-02-10 | 1977-09-15 | Organon Nv | Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen. |
| NL154598B (nl) | 1970-11-10 | 1977-09-15 | Organon Nv | Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking. |
| NL154599B (nl) | 1970-12-28 | 1977-09-15 | Organon Nv | Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen, alsmede testverpakking. |
| US3901654A (en) | 1971-06-21 | 1975-08-26 | Biological Developments | Receptor assays of biologically active compounds employing biologically specific receptors |
| US3853987A (en) | 1971-09-01 | 1974-12-10 | W Dreyer | Immunological reagent and radioimmuno assay |
| US3867517A (en) | 1971-12-21 | 1975-02-18 | Abbott Lab | Direct radioimmunoassay for antigens and their antibodies |
| NL171930C (nl) | 1972-05-11 | 1983-06-01 | Akzo Nv | Werkwijze voor het aantonen en bepalen van haptenen, alsmede testverpakkingen. |
| US3850578A (en) | 1973-03-12 | 1974-11-26 | H Mcconnell | Process for assaying for biologically active molecules |
| US3935074A (en) | 1973-12-17 | 1976-01-27 | Syva Company | Antibody steric hindrance immunoassay with two antibodies |
| US3996345A (en) | 1974-08-12 | 1976-12-07 | Syva Company | Fluorescence quenching with immunological pairs in immunoassays |
| US4034074A (en) | 1974-09-19 | 1977-07-05 | The Board Of Trustees Of Leland Stanford Junior University | Universal reagent 2-site immunoradiometric assay using labelled anti (IgG) |
| US3984533A (en) | 1975-11-13 | 1976-10-05 | General Electric Company | Electrophoretic method of detecting antigen-antibody reaction |
| US4098876A (en) | 1976-10-26 | 1978-07-04 | Corning Glass Works | Reverse sandwich immunoassay |
| US4879219A (en) | 1980-09-19 | 1989-11-07 | General Hospital Corporation | Immunoassay utilizing monoclonal high affinity IgM antibodies |
| US5011771A (en) | 1984-04-12 | 1991-04-30 | The General Hospital Corporation | Multiepitopic immunometric assay |
| US4666828A (en) | 1984-08-15 | 1987-05-19 | The General Hospital Corporation | Test for Huntington's disease |
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| US4801531A (en) | 1985-04-17 | 1989-01-31 | Biotechnology Research Partners, Ltd. | Apo AI/CIII genomic polymorphisms predictive of atherosclerosis |
| US5272057A (en) | 1988-10-14 | 1993-12-21 | Georgetown University | Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase |
| US5192659A (en) | 1989-08-25 | 1993-03-09 | Genetype Ag | Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes |
| US5281521A (en) | 1992-07-20 | 1994-01-25 | The Trustees Of The University Of Pennsylvania | Modified avidin-biotin technique |
| US5747340A (en) | 1994-06-03 | 1998-05-05 | Syntex (U.S.A.) Inc. | Targeted gene expression using preproendothelin-1 promoters |
| JPH11511326A (ja) * | 1995-08-30 | 1999-10-05 | ジエンザイム コーポレイション | アデノウィルスおよびａａｖの精製 |
| AU732703B2 (en) * | 1996-11-20 | 2001-04-26 | Crucell Holland B.V. | An improved method for the production and purification of adenoviral vectors |
| CA2356373A1 (fr) * | 1998-12-31 | 2000-07-13 | Aventis Pharma S.A. | Methode de separation de particules virales |
| US6168941B1 (en) * | 2000-04-07 | 2001-01-02 | Genvec, Inc. | Method of producing adenoviral vector stocks |
| US20070286845A1 (en) | 2000-11-17 | 2007-12-13 | Vascular Biogenics Ltd. | Promoters exhibiting endothelial cell specificity and methods of using same for regulation of angiogenesis |
| WO2003039459A2 (en) * | 2001-11-05 | 2003-05-15 | Genvec, Inc. | Viral vector production methods and compositions |
| US7459154B2 (en) * | 2002-12-26 | 2008-12-02 | Cell Genesys, Inc. | Methods and reagents for the enhancement of virus transduction in the bladder epithelium |
| EP1844069A4 (en) * | 2005-01-28 | 2009-05-20 | Apollo Life Sciences Ltd | MOLECULES AND CHIMESE MOLECULES THEREOF |
| CA2658972C (en) | 2006-07-31 | 2019-11-26 | Vascular Biogenics Ltd. | Polypeptides and polynucleotides encoding same and use thereof in the treatment of medical conditions associated with ischemia |
-
2011
- 2011-01-12 WO PCT/IB2011/050137 patent/WO2011086509A1/en not_active Ceased
- 2011-01-12 EP EP11706326A patent/EP2523681A1/en not_active Withdrawn
- 2011-01-12 JP JP2012548518A patent/JP6009357B2/ja not_active Expired - Fee Related
- 2011-01-12 SG SG10201500015TA patent/SG10201500015TA/en unknown
- 2011-01-12 US US13/521,691 patent/US20130052165A1/en not_active Abandoned
- 2011-01-12 SG SG2012051496A patent/SG182490A1/en unknown
-
2012
- 2012-07-12 IL IL220922A patent/IL220922B/en active IP Right Grant
-
2013
- 2013-03-14 US US13/826,396 patent/US20130295053A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013516978A5 (enExample) | ||
| JP5465331B2 (ja) | 高細胞密度の培養物からのアデノウイルスの精製方法 | |
| JP5393896B2 (ja) | アデノウイルス粒子の精製方法 | |
| ES2329607T3 (es) | Metodos de purificacion de virus. | |
| ES2317517T3 (es) | Purificacion de virus usando ultrafiltracion. | |
| CN104694573B (zh) | 利用CRISPR/Cas9抑制HIV‑1感染原代淋巴细胞的方法 | |
| JP6009357B2 (ja) | アデノウイルスベクターの生産方法およびそれによって生成されるウイルス調製物 | |
| KR20150122674A (ko) | 아데노바이러스의 생산 방법 | |
| JP2000514290A (ja) | 組換えアデノウイルスの製造方法 | |
| CN104846013A (zh) | 一种复制缺陷型人55型腺病毒载体及其制备方法和应用 | |
| WO2015128500A1 (en) | A process for the preparation of group b adenoviruses | |
| CN105219740A (zh) | 一种重组人3型腺病毒及制备方法和应用 | |
| CN102284058A (zh) | 复制缺陷型抗ev71和ca16病毒双价疫苗的制备方法 | |
| CN116286685A (zh) | 一种基于CRISPR-Cas9技术的表达H9N2禽流感病毒XZ491毒株HA蛋白的重组血清4型禽腺病毒及其制备方法 | |
| US20080267992A1 (en) | Sars Virus Vaccine with Adenovirus Carrier and Preparation Method Thereof, and Use of Sars Virus S Gene for Preparation of Vaccine | |
| CN101768576B (zh) | Hsv1-tk基因重组溶瘤腺病毒及其制备方法和应用 | |
| CN107164337B (zh) | 含ccl5和sstr2基因的重组痘病毒及其制备方法 | |
| US20050079158A1 (en) | Construct of anti-cancer recombinant adenovirus, method for preparing the same and use thereof | |
| CN103881985B (zh) | 狂犬病病毒era减毒疫苗突变株及其制备方法和狂犬病活疫苗 | |
| CN101948516B (zh) | 一种以痘苗病毒载体为基础的反向遗传学系统建立及应用 | |
| CN1243099C (zh) | 灭活肿瘤chk1基因抗癌重组腺病毒构建体的获得及用途 | |
| CN1272440C (zh) | 以肿瘤细胞plk1为药靶的抗癌重组腺病毒的构建及用途 | |
| WO2012121071A1 (ja) | VA-RNAsが発現しないアデノウイルスベクター | |
| CN1237178C (zh) | 以肿瘤chk1为药靶抗癌重组腺病毒的构建方案及用途 | |
| CN118048323A (zh) | 一种表达h10n3禽流感病毒禽流感病毒ha蛋白的重组血清4型禽腺病毒及其构建方法 |